NIH Licenses Custom T-Cells to Hunt Down AML
Published Date: 7/24/2026
Notice
Summary
The government has developed special T cell receptors that can target a tough type of blood cancer called acute myeloid leukemia (AML), especially in patients with a specific genetic marker. These new receptors promise safer, more precise treatment with fewer side effects than current options. Researchers and companies can now license this invention to help bring this exciting therapy to patients faster.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
NCI Offers License for AML TCRs
The National Cancer Institute (NCI) is seeking research co-development partners or licensees for two T cell receptors, TCR6 and TCR7, that target mutant NPM1 in acute myeloid leukemia. The technology is listed under NIH Reference Number E-200-2025-0 and a U.S. provisional patent application (63/908,266) was filed October 30, 2025.
Targeted Therapy Opportunity for AML
These TCRs (TCR6 and TCR7) recognize the neoepitope AVEEVSLRK derived from mutant NPM1 when presented by HLA-A*11:01 and showed robust, specific killing of AML cell lines and patient-derived samples with no detected cross-reactivity to normal blood cells in pre-clinical testing. This represents a potential adoptive T cell therapy option for acute myeloid leukemia patients who have the NPM1 mutation and HLA-A*11:01, and the development stage is listed as Pre-clinical (in vivo validation).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
2026-14848, Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS
The National Institutes of Health plans to give Modala Bio an exclusive license to use new RXFP1 agonist inventions that could help treat diseases like cancer, heart failure, and fibrosis. This means Modala Bio gets special rights to develop and sell these promising medicines worldwide. If you want to comment or apply for a license, you have until August 24, 2026, so don’t miss out!
2026-14752, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in August 2026 to review and evaluate important grant and contract proposals. These meetings protect private info and trade secrets while deciding who gets funding to fight antibiotic resistance, support schizophrenia research, and boost medical tech. If you’re involved in these fields, keep an eye on these dates—they could impact future research dollars and projects.
2026-14666, National Institute of Neurological Disorders and Stroke; Notice of Meeting
The National Institute of Neurological Disorders and Stroke is hosting a free, virtual meeting on August 24, 2026, to talk about Parkinson’s disease research, care, and services. This meeting affects people with Parkinson’s, their families, and organizations working on the disease, as it will share updates and plan a federal list of Parkinson’s programs. Public comments are welcome until August 10, giving everyone a chance to join the conversation and help shape future efforts.
Previous / Next Documents
Previous: 2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Next: 2026-14982, Agency Information Collection Activities; Comment Request; Approved State Ability To Benefit Process
The Department of Education wants to keep collecting info about how states check if students can benefit from federal student aid, without changing anything. This affects students and schools involved in federal aid programs and helps keep the process smooth. You’ve got until September 22, 2026, to share your thoughts—no cost changes, just a paperwork check-in!